Dose-Comparison Study to Evaluate the Safety and Immunogenicity of MEDI-517 (GSK 580299) in Healthy Adult Females

NCT00693966 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

210

Enrollment

INDUSTRY

Sponsor class

Conditions

Infections, Papillomavirus

Interventions

BIOLOGICAL: MEDI-517 HPV-16/18 VLP AS04 vaccine (Formulation 1)
BIOLOGICAL: MEDI-517 HPV-16/18 VLP AS04 vaccine (Formulation 2)
BIOLOGICAL: MEDI-517 HPV-16/18 VLP AS04 vaccine (Formulation 3)
BIOLOGICAL: MEDI-517 HPV-16/18 VLP with Al(OH)3 (Formulation 4)

Sponsor

GlaxoSmithKline